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receptors to enhance the delivery of gold
nanoparticles into colorectal cancer cells in vitro
Nakul Patel, * Lucy Ghali, Ivan Roitt, Leonardo Puntoja Munoz
and Richard Bayford
Colorectal cancer (CRC) is the fourth most common cancer in the world. Due to its asymptomatic nature,
CRC is diagnosed at an advanced stage where the survival rate is <5%. Besides, CRC treatment using
chemotherapy, radiotherapy and surgery often causes undesirable side-effects. As such, gold
nanoparticles (GNPs) are envisaged in the field for the diagnosis and treatment of CRC. GNPs have
unique physical, chemical and electrical properties at the nanoscale which make them suitable for
application in biomedicine. However, for GNPs to become clinically effective, their internalisation
efficiency in cancer cells must be enhanced. Folate receptor-a (FR) is overexpressed in CRC cells
wherein FR helps in the uptake of folic acid within the cells. Tyro3, a novel tyrosine kinase receptor,
drives cell proliferation and its overexpression is correlated with poor prognosis in CRC. Their
upregulated expression in CRC cells relative to normal cells makes them an ideal target for GNPs using
active targeting. Therefore, in this study receptors FR and Tyro3 were simultaneously targeted using
specific antibody-coated GNPs in order to enhance the uptake and internalisation of GNPs in CRC cells
in vitro. Four different types of coated-GNPs were synthesised GNPs-PEG, GNPs-anti-FR, GNPs-anti-
Tyro3 and GNPs-anti-(FR + Tyro3) and incubated (0–50 ng) with three CRC cell lines namely CRL1790,
CRL2159 and HCT116. Simultaneous targeting of these receptors by GNPs-anti-(FR + Tyro3) was found
to be the most effective in internalisation in CRC cells compared with GNPs targeted singly to FR or
Tyro3 (p <0.05). Besides this, results show that Tyro3 mediated similar internalisation efficacy to FR (p
<0.05) in CRC cells using ICP-OES.1 Introduction
Colorectal cancer (CRC) ranks fourth inmortality andmorbidity
worldwide and is characterised by the formation of malignant
neoplasms in the mucosa of the colon and rectum.1,2 In CRC,
early diagnosis and treatment is key to treating the disease as
CRC remains asymptomatic and develops over the span of 10
years.3 Adjuvant chemo-radiotherapy and surgery are the only
alternatives to treating CRC, but due to late diagnosis, not all
patients respond to therapeutic regimes properly and, there-
fore, no one magic bullet can target CRC. Also, toxic side-effects
associated with the treatment such as vomiting, diarrhoea,
blood and hair loss, proteinuria, etc can have an overwhelming
effect on a patient's routine life.4 Additionally, the results of the
surgery too are not noteworthy as it relies on radiotherapy and
chemotherapy for its success. Hence, the need to develop
a personalised tailor-made therapy specic for CRC remains
indispensable.5 To that end, nanotechnology is utilised in order
to circumvent the above-mentioned drawbacks.lesex University, The Burroughs, Hendon,
0@yahoo.com
the Royal Society of ChemistryNanotechnology is evolving as a novel area in scientic
research and has led to advances in the eld of cancer therapy,
drug delivery, biological sensors, microbiology, heart disease,
etc.6 Gold nanoparticles (GNPs) refer to particles constituted of
gold (Au) atoms with sizes ranging between 2 nm and 100 nm
that are derived by reducing gold-based compounds such as
HAuCl4.7,8 GNPs have a unique physicochemical feature of
readily forming thiol and amine bonds as well as intrinsic
surface plasmon resonance (SPR), a property whichmakes them
versatile in biological applications. SPR refers to the collective
oscillation of electrons by absorbing photons from light at
a specic wavelength and emitting the energy dependent upon
the size and shape of the GNPs. SPR of GNPs can be tuned to
resonate with the specic wavelength of light in the visible or
infrared spectrum. Hence, monitoring the therapy, imaging,
drug delivery and biomedical imaging using a contrast agent,
diagnosing and hyperthermia therapy could be possible.5
Additionally, GNPs are shown to be non-toxic to the cells as the
core of GNPs is inert.9
GNPs have a wide spectrum of applications in genomics,
biosensors, immunoassays, clinical studies, drug discovery,
































































































View Article Onlineapplication in cancer diagnosis and therapy is most prom-
ising.10 GNPs can be delivered by linking molecules that can
recognise the proteins/molecules on the CRC cell surface in
a process called ‘active targeting’. In contrast, in passive tar-
geting, due to leaky and poorly developed blood vessels with
enlarged pores (100–600 nm), GNPs can preferentiallyFig. 1 Schematic representation shows the synthesis of FR and Tyro3 ant
assessment via ICP-OES.
Nanoscale Adv.accumulate in the tumour.11 Also, with underdeveloped
lymphatic vessels, GNPs are improperly drained from the
tumour. As such, they target the CRC tumour passively in
a process called the enhanced permeability effect (EPR).12 As
a result, GNPs (10–200 nm) penetrate the tumour and accu-
mulate prior to reaching the cell cytoplasm.13 Consequently,ibody-coated GNPs, incubation with all three cell lines and subsequent
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 2 UV-vis spectra of all 4 GNP constructs GNPs-PEG, GNPs-anti-
































































































View Article Onlinethis results in increased delivery of drugs ferrying GNPs into the
tumour.14
Currently, applications of nanomedicine can be hindered by
problems of toxicity and delivery.15 Nanomaterials administered
in vivo spread throughout the body and can reach off-target sites
and damage healthy cells and tissues. Consequently, this lowers
their efficacy in reaching the target site leading to non-specic
accumulation and unwanted side-effects.16 For GNP application
in vivo, they need to reach directly the tumour site to enhance
their subsequent uptake by the tumour cells.17 These obstacles
must be addressed in order to improve the efficacy of using
GNPs for delivery and, therefore, efficient delivery of GNPs
which must be attained for their biomedical application such as
imaging, detection/diagnosis and therapy.18–20 To overcome
these drawbacks and in order to increase the GNP internal-
isation and delivery efficacy, two different receptors folate
receptor-a (FR) and Tyro3 receptor on CRC cells were selected
simultaneously for active targeting.
FR is overexpressed in various malignancies such as breast,
colon, ovarian, endometrium, kidney, brain andmyeloid cells.21
This folate receptor is limited or absent in non-proliferating
normal cells which helps to distinguish tumour cells from
normal healthy cells.22 FR is a membrane-bound receptor and
participates in the transport of folate into the cells.23 FR is
present in four different isoforms (a, b, g and d) and different
tissues express different isoforms. In cancer, folate receptor-a is
overexpressed in colon, ovary, breast and head and neck cancers
constituting up to 40% in human cancers.24 FR-b is upregulated
in brain, liver, thyroid, uterus, stomach, prostate, testis and
colon cancers.24 Therefore, due to folate receptor-a's over-
expression in different cancers, especially in CRC, we selected it
as a targeting moiety.25
Tyro3, together with Axl and Mer, constitutes the TAM
receptor family and is a subfamily receptor of tyrosine kinases
discovered in 1991.26 In 1993, Tyro3 receptor, also known as Tif,
Sky, BYK and Dtk,27 was discovered to have a role in embryonic
differentiation.28 In 1995, proteins Gas6/protein S (Pros1) were
identied as ligands for these TAM receptors.29 TAM mediates
signal transduction through the binding of Gas6/Protein S fol-
lowed by homodimerisation or heterodimerisation of its
receptors and autophosphorylation of the tyrosine residue in
the kinase domain.30 Tyro3's oncogenic potential rst emerged
when murine models were shown to have mammary tumours
due to the upregulation of TAM receptors.31 Tyro3 can also be
activated in ligand-independent activation when expressed in
high concentrations.32 Similar to FR, Tyro3 receptor is also
upregulated in various human cancers including CRC and its
overexpression is correlated with poor prognosis and advanced
tumour stage.33 For example, in a study conducted in CRC
patients, it was found that Tyro3 was overexpressed in CRC
tumour patients compared with healthy colon mucosa (p
<0.0001). It was also shown that overexpression of Tyro3 led to
CRC and metastasis in the liver, making Tyro3 a potential target
in CRC.30 In another study comparing 76 polyps and 265 pairs of
normal and cancer samples, overexpression of Tyro3 was found
to greatly enhance cell motility, invasion, anchorage-indepen-
dent growth and metastatic ability in CRC and induces© 2021 The Author(s). Published by the Royal Society of ChemistryEndothelial to Mesenchymal Transition (EMT).27 Moreover, no
clinical trials so far have been shown to have targeted the Tyro3
receptor, making Tyro3 a novel target in CRC.30,34 Besides CRC,
Tyro3 as a novel target was also demonstrated in Hepatocellular
Carcinoma (HCC) wherein samples from 55 patients showed
two-fold expression of Tyro3 in the cancerous tissue compared
to normal tissue.35 Therefore, the aim of the current study was
to target FR and Tyro3 receptors simultaneously in order to
increase the efficacy of GNP delivery and internalisation in CRC
tumour cells. Fig. 1 shows a schematic representation of the
entire research.2 Results and discussion
2.1 Gold nanoparticle characterisation by UV-vis
spectroscopy and DLS
Ultraviolet visible (UV-vis) spectroscopy is a vital technique in
determining the GNP size distribution, concentration and
aggregation levels. Hence, UV-vis spectra were used to deter-
mine the characteristics and attachment of the FR and Tyro3
antibodies to the GNPs. For GNPs-PEG, the SPR peak was found
at 513 nm but aer conjugation the peak shied towards
a longer wavelength.36 Newly synthesised GNPs-anti-FR and
GNPs-anti-Tyro3 had respective lmax at 517 nm whereas for
GNPs-anti-(FR + Tyro3) the lmax was at 516 nm (Fig. 2). These
newly formed SPR peaks were associated with red shis (4 nm
and 3 nm) due to the change in the local refractive index indi-
cating the addition of antibody layers around the GNPs.37 Table
1 provides an overview of all 4 GNPs and their respective UV-vis
spectra. A similar red-shi (<10 nm) was also reported when the
Epidermal Growth Factor Receptor (C225) antibody was conju-
gated to GNPs with an alkane-thiol linker.38
The stability of GNPs was also determined via inducing
aggregation. Aggregation of GNPs will induce a red shi
towards the infrared region of the spectrum and broadening of
the SPR peak.39 As such, GNPs-anti-FR (Fig. 3a), GNPs-anti-
Tyro3 (Fig. 3b) and GNPs-anti-(FR + Tyro3) (Fig. 3c) were tested
with different concentrations of NaCl for 1 hour to determine
the stability in the solution. For all three types of GNPNanoscale Adv.
Table 1 Table summarises the characteristics of all 4 GNP constructs using UV-visible spectroscopy and dynamic light scattering (DLS)
Types of GNP constructs UV-vis spectrophotometry DLS (nm) Zeta Potential (mV) PDI
GNPs-PEG 513 nm 22.97 nm  2.1 18.7 mV  1.5 0.204
GNPs-anti-FR 517 nm 30.78 nm  1.8 1.86 mV  2.3 0.231
GNPs-anti-Tyro3 517 nm 30.96 nm  2.2 2.32 mV  1.9 0.142
































































































View Article Onlineconstructs, no observable red shi or broadening of the peaks
was seen indicating that all three constructs were highly stable.
Dynamic light scattering (DLS) is also commonly used to
determine the hydrodynamic size and zeta potential of the
nanoparticles in the suspension in the nanometre range. The
size of GNPs-PEG was measured to be 22.97 nm (Fig. 4a).
However, aer the addition of the FR and Tyro3 antibodies, the
overall size of the GNPs-anti-FR and GNPs-anti-Tyro3 increased
to 30.78 nm and 30.96 nm, respectively (Fig. 4b and c). The
molecular mass of the antibodies used is 150 kDa and their
corresponding size is around 7–10 nm.40 Therefore, the overall
increase in the GNP hydrodynamic size of approximately 8–10
nm is attributed to the attachment of the antibodies to GNPs.
Similarly, the hydrodynamic diameter of GNPs-anti-(FR + Tyro3)
was 31.36 nm (Fig. 4d) conrming the attachment of both FR
and Tyro3 antibodies to GNPs. Additionally, the polydispersity
index (PDI) for all types of GNPs was <0.3 indicating a narrowFig. 3 The stability of (a) GNPs-anti-FR (b) GNPs-anti-Tyro3 and (c) GNPs
1 M). UV-vis peak shows no red-shift or broadening of the peak. For each
and Y-axis represents the Optical Density (OD).
Nanoscale Adv.monodisperse GNP suspension (Fig. 4). The zeta potential of
GNPs in the suspension was also measured and as a result all
GNPs conferred a net negative charge. GNPs-PEG had an overall
negative charge (18.7 mV). However, once respective anti-
bodies (FR and Tyro3) were conjugated, it changed the overall
dielectric state of the nanoparticles lowering the zeta potential
values.41 As a result, GNPs-anti-FR, GNPs-anti-Tyro3 and GNPs-
anti-(FR + Tyro3) had signicantly lower zeta potentials
compared to GNPs-PEG (Table 1). Taken together, UV-vis and
DLS studies show that GNP conjugates are highly stable,
monodisperse and bonded with respective antibodies.2.2 Bradford assay to quantify antibody attachment
A modied Bradford assay was used to quantify antibody
conjugation to GNPs. The assay involves the use of the dye
Coomassie Brilliant Blue G-250 for the quantication of
proteins. First, the Bradford assay was performed to determine-anti-(FR + Tyro3) at different NaCl concentration solutions (0.001M
UV-vis spectrum, X-axis represents the wavelength in nanometres (nm)
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 4 Hydrodynamic size of GNPs is shown in (a)–(d) of GNPs-PEG, GNPs-anti-FR, GNPs-anti-Tyro3 and GNPs-anti-(FR + Tyro3), respectively.
































































































View Article Onlinethe amount of antibodies in the supernatant obtained aer the
centrifugation and incubation of GNPs with respective anti-
bodies. A standard solution of IgG was used to generate a cali-
bration curve to quantify the unbound antibodies in the
supernatant. Thereaer, the number of antibodies conjugated
to GNPs was calculated via the difference between the initial
concentration used and concentration found in the supernatant
(Fig. 5). Consequently, the number of antibodies (IgG) bound to
one GNP was calculated to be 7.42 Table 2 summarises the
calculation of antibody molecules attached to each type of GNP
construct. The number of antibodies attached to a single GNP is
consistent with that quantied in two separate studies.37,43Fig. 5 Calibration curve using IgG antibodies in the Bradford assay.2.3 Matrix associated laser desorption/ionisation time-of-
ight (TOF) mass spectroscopy (MALDI-TOF)
MALDI-TOF was implemented to further conrm the attach-
ment of IgG (anti-FR and anti-Tyro3) to all the antibody-coated
GNP constructs. Intensity peaks were conrmed using IgG as© 2021 The Author(s). Published by the Royal Society of Chemistrythe standard. Three intensity peaks were observed [M + H]+, [M
+ 2H]2+ and [M + 3H]3+ (Fig. 6a) generated from IgG as shown
previously.44,45 Out of the three peaks, IgG is mainly denoted by
two main peaks [M + H]+ and [M + 2H]2+ corresponding to singleNanoscale Adv.
Table 2 Table illustrates the amount of IgG (anti-FR and anti-Tyro3) antibodies bound to different types of GNP constructs




the Bradford assay Antibody attached
Antibody coated
to one gold nanoparticle
GNPs-anti-FR 200 mg 1.7 mg 198.3 mg  1.2 7.23  0.3
GNPs-anti-Tyro3 200 mg 2.1 mg 197.9 mg  1.4 7.19  0.2
































































































View Article Onlineprotonated (m/z ¼ 148 286) and double protonated (m/z ¼
74 478) IgG molecules.46,47 For all the antibody-coated GNPs
(Fig. 6c), (Fig. 6d) and (Fig. 7), similar peaks were also seen
which conrmed the attachment of the antibodies to GNPs-PEG
(Fig. 6b). As a proof of principle, GNPs-PEG were also analysed
using MALDI-TOF and showed no similar IgG peaks in the
sample due to the absence of the antibodies. This furtherFig. 6 MALDI-TOF spectra for (a) IgG as the standard, (b) GNPs-PEG, (c) G
for IgG [M + H]+ ¼ m/z 148 286, [M + 2H]2+ ¼ 74 478 and [M + 3H]3+ ar
absent in GNPs-PEG.
Nanoscale Adv.conrmed that those peaks were emanating from IgG only and
not generated from either the GNPs, polyethyleneglycol chain or
the matrix used to analyse the GNPs.2.4 FR and Tyro3 expression levels in different cell lines
For targeting and testing of GNPs, FR and Tyro3 were assayed
for their expression levels in the colon epithelial cell lineNPs-anti-FR and (d) GNPs-anti-Tyro3 are shown. High intensity peaks
e seen. Spectra in (c) and (d) show the same peaks, however, they are
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 7 MALDI-TOF spectrum for GNPs-anti-(FR + Tyro3) also shows all three intensity peaks representative of IgG antibodies.
Fig. 8 Figure shows the relative expression of FR in all three cell lines. DAPI stains the nucleus blue while FITC stains the FR membranous
receptors in green. (a) Colon epithelium (CRL1790), (b) Duke’ B carcinoma (CRL2159) and (c) Colorectal carcinoma (HCT116). Clear expression

































































































View Article Online(CRL1790) vs. CRC cell lines (CRL2159 and HCT116). FR is
a membrane bound receptor and was found to be overexpressed
in CRL2159 and HCT116 CRC cell lines whereas it was absent in
CRL1790 in ICC experiments (Fig. 8). FR is upregulated in many
cancers such as brain, kidney, breast, ovarian, and colon.22 Due
to the fact that FR is absent or minimally expressed in normal
colonic tissue, it makes it a potential target for GNP application
in biomedicine.48 Tyro3 is another subtype of tyrosine kinase
and a membrane bound receptor along with others such as
EGFR, VEGFR, PDGFR, IFF1R andMET.35 Tyro3 had been found
to be overexpressed in various cancers including CRC.41 In ICC
experiments, its expression patterns too were concomitant with
the literature and were not expressed in CRL1790 compared to
CRL2159 and HCT116 (Fig. 8).27,30 Thus, FR and Tyro3 receptors
are overexpressed in CRC cells compared to colon epithelial
cells making them a feasible target for GNPs. Hence, they were
used simultaneously to target the cells by exploiting their
upregulation in CRC cells in order to increase the efficiency of
GNP delivery to the targeted tumour cells (Fig. 9).2.5 Inductively coupled plasma-optical emission
spectroscopy (ICP-OES)
To study the internalisation and efficacy of all GNP constructs,
elemental analysis was conducted using the ICP-OES technique.
Aer binding with the receptors on the plasma membrane of© 2021 The Author(s). Published by the Royal Society of Chemistrythe cells, GNPs become internalised via receptor-mediated
endocytosis (RME).49 Different amounts of all types of GNPs (0–
50 ng) were aliquoted in wells for each of the three cell lines.
Aer 4 hours of incubation, the cells were thoroughly washed,
and then digested in aqua regia before being subjected to ICP-
OES. CRL1790 has shown the least internalisation with less
than 10 ng for all the GNP concentrations (Fig. 10). In CRL1790,
uptake of antibody-coated GNPs was greater than that observed
for GNPs-PEG alone (p <0.05). An important observation was
also made that there was no difference in internalisation in
single antibody-coated GNPs (GNPs-anti-FR & GNPs-anti-Tyro3)
vs. double antibody-coated GNPs (GNPs-anti-(FR + Tyro3)) (p
>0.05). Both of these observations can be attributed to the low
number of FR and Tyro3 receptors in CRL1790.
In CRL2159, there was an increase in GNP uptake for single
antibody-coated GNPs (p <0.05) and double antibody-coated
GNPs (p <0.05) compared to GNPs-PEG (Fig. 11). Also, compared
to GNPs-PEG, GNPs-anti-FR, GNPs-anti-Tyro3 and GNPs-anti-
(FR + Tyro3) had more internalisation for each and every
concentration of the incubated GNPs. At 20 ng, GNPs-anti-FR
and GNPs-anti-Tyro3 were internalised more than 10 ng in
CRL2159 compared to below 10 ng in CRL1790 (p <0.05). This
could be explained by the overexpression of FR and Tyro3
receptors in CRL2159, as a result of which there was a two-fold
increase in RME and internalisation compared to CRL1790.
Additionally, double antibody-coated GNPs were highly efficientNanoscale Adv.
Fig. 9 Figure shows the relative expression of the Tyro3 receptor in three types of cell lines. DAPI stains the nucleus blue while FITC stains the
Tyro3 membranous receptor in green. (a) Colon epithelium (CRL1790), (b) Duke’ B carcinoma (CRL2159) and (c) colorectal carcinoma (HCT116).
Clear expression patterns can be seen from the Tyro3 receptor being upregulated in CRL2159 and HCT116 compared to CRL1790. Scale bar¼ 50
mm. Magnification 40.
Fig. 10 Internalisation of all 4 GNP constructs in CRL1790 cell lines.
Internalisation is shown for each well. Experiments were done in
triplicate (n¼ 3). ANOVA¼ p <0.05. Standard error of mean represents
































































































View Article Onlinein targeting CRL2159 cells compared to single antibody-coated
GNPs (p <0.05). Most importantly, no signicant difference in
internalisation efficiency was observed between FR and Tyro3Fig. 11 Internalisation of all 4 GNP constructs in CRL2159 cell lines.
Internalisation is shown for each well. Experiments were done in
triplicate (n¼ 3). ANOVA¼ p <0.05. Standard error of mean represents
three or more replicates.
Nanoscale Adv.targeted single antibody-coated GNPs (p >0.05). This means that
GNPs-anti-Tyro3 had the same internalisation capability as
GNPs-anti-FR. This observation that the Tyro3 receptor can be
equally capable as FR in targeting CRC using GNPs is a novel
nding. The graph also demonstrates there was a very low
uptake of GNPs-PEG in CRL2159 (Fig. 11) particularly when
compared to single and double antibody-coated GNPs.
A similar pattern was also seen for the HCT116 colorectal
carcinoma cell line (Fig. 12). For every concentration of all
single and double-antibody coated GNPs, there was an
increased internalisation efficiency compared to GNPs-PEG.
However, at 50 ng there was a non-specic uptake that could be
explained by the high number of non-targeted GNPs. This set of
results also show that HCT116 had a high number of internal-
ised GNPs compared to CRL1790 and CRL2159 which can be
attributed to overexpression of FR and Tyro3 receptors and
a different method of endocytosis mechanism pertaining to an
individual cell line.50 Such results also indicate that double
antibody-coated GNPs had a higher internalisation efficiencyFig. 12 Internalisation of all 4 GNP constructs in HCT116 cell lines.
Internalisation is shown for each well. Experiments were done in
triplicate (n¼ 3). ANOVA¼ p <0.05. Standard error of mean represents
three or more replicates.
































































































View Article Onlinecompared to single antibody-coated GNPs (p <0.05). Moreover,
the GNPs-anti-Tyro3 had similar internalisation efficacy to
GNPs-anti-Tyro3 since there was no signicant difference in
their uptake (p >0.05) showing that the Tyro3 receptor had an
equal potential for the uptake of GNPs as the FR receptor.2.6 Cell uptake studies using confocal microscopy
Conjugation of FITC antibody-coated GNPs has enabled
confocal microscopy imaging to determine cellular uptake and
localisation (Fig. 13). A concentration of 50 ng was chosen for
the experiment since the uorescent signals were constant
compared to other concentrations used and also were the most
internalised concentration as determined using ICP-OES. In theFig. 13 Figure shows internalisation of GNPs-anti-FR, GNPs-anti-Tyro3
Nuclei were stained in blue and GNPs in green. Experiments were repea
© 2021 The Author(s). Published by the Royal Society of Chemistrypresent experiment, GNPs-anti-FR, GNPs-anti-Tyro3 and GNPs-
anti-(FR + Tyro3) were successfully used to target cancer cells
using FR and Tyro3 receptors as quantied by ICP-OES.
CRL1790 gave reduced non-specic binding or no signal due to
low expression of FR or Tyro3 receptors on these CRC cells. On
the other hand, CRL2159 and HCT116 had overexpressed FR &
Tyro3 receptors and, therefore, had more internalisation of
GNPs which was also supported by ICP-OES (Fig. 11) and
(Fig. 12). Similar results can also be seen with strong green
uorescence associated with GNP uptake (Fig. 13). As
a comparison, cells from all three cell lines without GNPs are
also shown in Fig. 14. In a separate study, electron microscopy
had demonstrated 4 nm and 6 nm internalisation by HeLa cellsand GNPs-anti-(FR + Tyro3) (red arrows) at 50 ng in all three cell lines.
ted in triplicate (n ¼ 3). Scale bar ¼ 50 mm. Magnification 40.
Nanoscale Adv.
Fig. 14 All three cell lines (A) CRL1790, (B) CRL2159 and (C) HCT116 from confocal microscopy are shown. The images are represented as

































































































View Article Onlineand the NPs were sub-localised in endosomes and lysosomes.51
In another experiment to demonstrate the uptake, HeLa cells
were incubated with folate-conjugated GNPs. GNPs were shown
via confocal and electron microscopy to be localised in the
cytoplasm due to overexpressed folate receptors.41 These results
strongly suggest that the presence of GNPs in the cytoplasm was
due to receptor mediated endocytosis (RME) via invagination of
the plasma membrane in the cytoplasm. Results as shown in
Fig. 13 are also in line with the experiments conducted here and
previous literature as stated above conrming the hypothesis
that simultaneous targeting of FR and Tyro3 receptors has led to
an increase in cellular uptake of GNPs.3 Materials and methods
3.1 Cell culture
Human Colon Epithelium Cell Line CRL1790 (ATCC no.
CCD841), Human Colorectal Cancer Duke's B CRL2159 (ATCC
no. LS411N) and Colorectal Carcinoma HCT116 (ATCC no. CCL-
247) were used to grow and test the efficiency of gold nano-
particles. CRL1790 was cultured using Sigma's Minimum
Essential Medium (MEM) Eagle (product no. M4655) supple-
mented with 10% (v/v) Foetal Bovine Serum (FBS) and 1%
Penicillin/Streptomycin (v/v) antibiotic solution. CRL2159 was
cultured using Sigma's RPMI1640 (product no. R8758)Fig. 15 Figure shows the attachment of antibodies to GNPs-PEG.
Nanoscale Adv.supplemented with 10% FBS and 1% antibiotic solution.
HCT116 was cultured using Gibco's Dulbecco's Modied Eagle
Medium (DMEM) solution (product no. 61965-026) and sup-
plemented with 10% FBS and 1% antibiotic solution. The cells
were passaged at 80–90% conuence, once or twice a week.
Approximately, 10 000 cells per well were aliquoted in 6-well
plates and allowed to reach 80–90% conuency before ali-
quoting GNPs with different targeting moieties for the purpose
of testing the efficiency.3.2 Synthesis of different types of GNPs
Schematic representation of the study is shown in Fig. 1. To test
the hypothesis that targeting FR and Tyro3 simultaneously
leads to a higher concentration of GNPs in the cells, pegylated
GNPs (GNPs-PEG), folate receptor-a antibody bound GNPs
(GNPs-anti-FR), Tyro3 receptor antibody bound GNPs (GNPs-
anti-Tyro3) and both antibodies specic for FR and Tyro3
receptor (1 : 1) attached GNPs (GNPs-anti-(Tyro3 + FR)) were
tested in Colon Epithelium (CRL1790), Duke's Carcinoma
(CRL2159) and Colorectal Carcinoma (HCT116) cell lines to
investigate the uptake of these constructs. To synthesise the
above-mentioned GNPs, lyophilised GNPs with a polyethylene
glycol (PEG) (5 kDa) linker, a NHS ester-activated kit was
purchased from Cytodiagnostics (product no. CGN5K-5-2) and
































































































View Article Online(product no. MA-23917) or Tyro3 antibodies (product no.
ab235078) were reacted with NHS-activated GNPs for 2 hours to
yield GNPs-anti-FR and GNPs-anti-Tyro3 conjugates. For GNPs-
anti-(FR + Tyro3), a 1 : 1 ratio was used whilst reacting respec-
tive antibodies with NHS-activated GNPs. The solution was then
centrifuged at 15 000g for 1 hour using 100 kDa membrane
lters (product no. VS0152) to remove the unbound antibodies
from the antibody-conjugated GNPs. GNPs-PEG were syn-
thesised by activating the GNPs rst without any antibodies
resulting in pegylated GNPs. Synthesised conjugates were then
stored in gold nanoparticle buffer at 4 C where they were stable
for 3 months. The nal volume had approximately 1.1  1014
GNPs in accordance with the information provided by the
company.
Due to the fact that uorescein isothiocyanate (FITC)
recognises and binds to primary amine residues found on
monoclonal antibodies, all antibody-coated GNPs were reacted
with 0.1 mol L1 FITC for 24 hours in the dark on an orbital
shaker to enable visualisation using confocal microscopy.41
FITC labelled GNP conjugates were then centrifuged using
10 000 MW Amicon® centrifugal lter tubes to remove excess
FITC from the suspension. GNPs-PEG were the only exception
since they do not provide a supporting amino group to bind
FITC and, thus, were not included in the confocal imaging
experiment. Since confocal imaging is used to qualitatively and
solely assess the localisation of single- and double-antibody-
coated GNPs in the cytoplasm, inclusion of GNPs-PEG would be
an irrelevant experiment. ICP-OES was used to quantify the
uptake of GNPs-PEG in all three cell lines as a control.
3.3 Ultraviolet visible (UV-vis) spectroscopy
All UV-spectra were recorded using the BMG FLUstar Omega
soware to read the absorbance at room temperature. Briey,
300 ml of GNPs-PEG, GNPs-anti-FR, GNPs-anti-Tyro3 and GNPs-
anti-(FR + Tyro3) were aliquoted into a 96-well plate (96NUN)
and readings were recorded between 400 and 800 nm. Colloidal
stability of the nanoparticles in biological media is equally
crucial to preserve their utility as aggregation oen leads to an
undesirable biological response. A quantitative measurement of
nanoparticle aggregation in solution would provide a valuable
assessment of colloidal stability of bio-nano interfaces aer
surface functionalization. As such, 1 ml GNPs-PEG, GNPs-anti-
FR, GNPs-anti-Tyro3 and GNPs-anti-(FR + Tyro3) were incubated
with 100 ml of varied NaCl concentrations (0.01 M, 0.1 M, 0.5 M
and 1 M) for 1 hour at room temperature. This provided a check
for aggregation via a red-spectral shi in the SPR peak of all the
GNP constructs using a UV-vis spectrophotometer.
3.4 Dynamic light scattering (DLS)
The dynamic light scattering apparatus (DLS) (Malvern Nano-
ZS) was used to record the distribution of the size of the
nanoparticles and zeta potential in the suspension. Disposable
cuvettes were used to determine the size of the respective GNPs.
1.5 ml GNPs solution was loaded into the DLS and measure-
ments were taken. Readings were taken in triplicate for every
GNP conjugate.© 2021 The Author(s). Published by the Royal Society of Chemistry3.5 Bradford assay
To quantify the antibodies attached to all the GNP constructs,
the Bradford assay was performed. A calibration curve was
plotted in the range of 0 to 50 mg ml1 using IgG antibodies
(product no. 56834–25 MG) in 1 PBS buffer (pH 7.4) as the
standard (R2¼ 0.997) (Fig. 5). Briey, in a 96-well plate, 100 ml of
supernatants from GNPs-anti-FR, GNPs-anti-Tyro3 and GNPs-
anti-(FR + Tyro3) were aliquoted and incubated with 150 ml of
Bradford reagent (catalog no. 23200). The samples were incu-
bated with Bradford reagent (lot no. SLBW5151) in the dark for
10 minutes. Subsequently, the absorbance readings were taken
at 595 nm to estimate the amount of antibodies attached to
each GNP construct by subtracting from the total amount
added. GNPs-PEG were not aliquoted since there was no anti-
body associated with this construct.3.6 FR and Tyro3 expression levels in different cell lines
CRL1790, CRL2159 and HCT116 were cultured and passaged as
mentioned above. For detecting differential expression of FR and
Tyro3 receptors in normal vs. CRC cell lines, the cells cultured on
sterilised coverslips were xed using 4% paraformaldehyde (PFA)
for 30 minutes. Aer xation, residual PFA was washed away by
washing twice with 1 PBS buffer aer which all three cell lines
were subjected to ICC experiments. Fixed cells, aer being washed
3 times with 1 PBS, were treated with citrate buffer at pH 6 for FR
antigen retrieval for 10 minutes whereas they remained untreated
for the Tyro3 receptor. The citrate treated cells were washed thor-
oughly with 1 PBS. Subsequently, 50% horse serum in 1 PBS
(1 : 1) was aliquoted to inhibit any unwanted signals and non-
specic binding of primary antibodies to the antigen receptors.
Thereaer, FR receptor alpha rabbit polyclonal antibody (no. PA5-
42004) at a concentration of 1 : 100 and Tyro3 mouse monoclonal
antibody (no. MA5-11171) at a concentration 1 : 50 were incubated
with all three types of cell line for 90 minutes followed by washing
with 1 PBS. Next, using the VECTASTATIN ABC kit (catalog no.
AK-6100), a biotinylated-secondary antibody was incubated with
the cells to facilitate binding with the primary antibodies for 30
minutes. Again, the residual unbound secondary antibody was
washed away using 1 PBS. Avidin-bound tertiary antibodies were
then aliquoted for 20minutes to bind to the biotinylated-secondary
antibodies at room temperature. The cells were washed with 1
PBS again. A tertiary peroxidase-labelled avidin was applied at
room temperature for 20 min before developing with a tyramide
signal amplication (TSA) uorescein system (NEN Life Science
Products, Boston, MA, USA) to enable the visualisation of the
receptors. Excess FITC was washed away using 1 PBS, and the
cover-slips were counter-stained using DAPI (40,6-diamidino-2-
phenylindole) (Product no. H-1200) based mounting media.
Confocal microscopy was used for obtaining pictures of FR and
Tyro3 expression.3.7 Matrix associated laser desorption/ionisation time-of-
ight (TOF) mass spectroscopy (MALDI-TOF)
The MALDI-TOF instrument (Bruker) was calibrated using IgG
































































































View Article OnlineThereaer, 1 ml GNPs-PEG, GNPs-anti-FR, GNPs-anti-Tyro3 and
GNPs-anti-(FR + Tyro3) conjugates were deposited on the target
plate to detect the presence of attached antibodies. The samples
were le to air-dry at room temperature. Subsequently, 1 ml of
sinapinic acid in acetonitrile and water (1 : 1) with 0.1% tri-
uroacetate (TFA) (70 : 30 v/v) was pipetted onto the dried
sample and le to form a thin layer over the sample at room
temperature. The mass spectra were acquired in a positive
linear mode with the laser beam at 60% intensity and 5000
shots on an average were red upon the sample to generate
protonated ions within the 20 000–200 000 m/z range. Spectra
were reviewed in FlexAnalysis Soware (Bruker) and visually
inspected for the presence of monoclonal peaks.3.8 Cell uptake studies using confocal microscopy
All 3 uorescently labelled GNP constructs GNPs-anti-FR, GNPs-
anti-Tyro3 and GNPs-anti-(FR + Tyro3) were subjected to
confocal microscopy. Normal Colon Epithelium (CRL1790),
Duke's B Colorectal Cancer (CRL2159) and colorectal carcinoma
(HCT116) were grown and cultured as mentioned above. Aer
trypsinisation, 10 000 cells were pipetted onto the sterilised
cover-slips in 6-well plates and placed in an incubator at 37 C at
5% CO2 to reach 80–90% conuence. Later, FITC bound anti-
body-coated GNPs (10–50 ng) were aliquoted in all three cell
lines and incubated for 4 hours. For a control, one well of each
cell line was incubated without GNPs. Thereaer, the media
were discarded and the non-bound GNPs were washed away by
using 1 PBS repeatedly over 4 times. 4% PFA was later pipetted
to x the cells for 30 minutes. The cells were again washed using
1 PBS twice and the cover-slips were mounted onto the slides
using DAP-based mounting media. Internalisation of FITC
bound GNPs was then visualised using a Leica confocal
microscope.3.9 ICP-OES
Quantication of GNPs in nanograms (ng) was carried out using
an ICP-OES (iCAP 6000 Series). The conditions of the ICP-OES
being operated upon are listed in Table 3. A gold standard
calibration curve (R2 ¼ 0.9946) was plotted using gold standard
solution (product no. 170321) in the range of 0–10 mg l1. All
three cell lines were grown and passaged as mentioned above
and later aliquoted in 6-well plates at approximately 10 000 cellsTable 3 Operating conditions of ICP-OES
Nebuliser Cross-ow
Spray chamber Glass-Scott type
Power (watts) 1150 watts
Coolant gas (L min1) 12 L min1
Auxiliary gas (L min1) 0.5 L min1
Nebuliser gas (L min1) 0.7 L min1
Viewing Axial
Sample uptake (ml) 1 ml
Analyte wavelength 242.795 nm
Measurement time per replicate (seconds) 30 s
R2 0.9946
Nanoscale Adv.per well. The cells were allowed to grow until they were 80–90%
conuent. GNPs-PEG and the antibody-coated GNPs were
incubated for 4 hours with all three cell lines. Aer incubation
with relevant GNPs, the cells were washed 4 times with 1 PBS
to remove free and loosely bound GNPs. Later, the cells were
digested using freshly prepared 1 ml aqua regia (3 : 1
HCL : HNO3) for 1 hour. Each digested sample with aqua regia
was later brought up to 10 ml by adding de-ionised water in 15
ml centrifuged tubes. Respective samples were then run
through an ICP-OES to measure the uptake of GNPs in nano-
grams. Concentrations (mg L1) obtained from ICP-OES were
used to determine the amount internalised by the cells in 10 ml
suspension using a C1V1 ¼ C2V2 formula.3.10 Statistics
Analysis of variance (ANOVA) was carried out where two or more
groups of means were involved and Student's unpaired t-test
where only two groups were compared. P#0.05 was considered
to be statistically signicant.4 Conclusion
CRC ranks fourth in mortality and morbidity worldwide
whereas diagnosis and treatment have shortcomings making
CRC patients' survival rate <5%. Therefore, targeting CRC cells
using GNPs could result in diagnosis and better treatment by
delivering contrast agents and drugs, respectively, in a selective
manner with minimum side-effects. To that end, this work
demonstrates targeting novel receptors Tyro3 and FR on CRC
cells simultaneously to enhance GNP delivery in vitro. The
minimum threshold levels of GNPs in CRC cells were higher via
targeting these receptors simultaneously compared to when
targeted individually. RME mediated localisation of GNPs was
also shown using confocal microscopy and concomitantly
quantied using ICP-OES. Similarly, depending on the cancer
types overexpressing specic receptors, GNPs can be exploited
for targeting using a similar principle to efficiently and specif-
ically deliver nanoparticles into cancer cells. Furthermore, the
work has also elucidated the internalisation of GNPs via the
novel receptor Tyro3 wherein it is equally effective as FR in
delivering GNPs in cancer cells. Therefore, by increasing
cellular delivery and internalisation, hyperthermia based
molecular imaging and treatments using GNPs can be made
feasible.52Author contributions
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